HOME >> BIOLOGY >> NEWS
OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine

Watertown, Massachusetts, July 2, 2003 OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that The Johns Hopkins University School of Medicine will begin a Phase I/II clinical trial of the Company's lead vascular targeting agent, Combretastatin A4 Prodrug (CA4P). The study will be conducted in patients with a retinal degenerative disease known as wet age-related macular degeneration (AMD). Between 2 million and 3 million people in the United States have significant vision loss caused by wet AMD.

"From a scientific perspective, this trial is significant because it marks the first study of a vascular targeting agent, initially developed to treat cancer, in patients with wet AMD," said Fred Driscoll, OXiGENE's president and chief executive officer. "From a corporate perspective, this trial strategically broadens our clinical development program into a second major area. Both oncology and ophthalmology offer significant market opportunities with unmet therapeutic needs."

Under the trial protocol, which was reviewed by the U.S. Food and Drug Administration, approximately 20 patients are scheduled to participate in the study. The study is now open for enrollment at Johns Hopkins' Wilmer Eye Institute in Baltimore, Maryland. The trial will be led by Quan Dong Nguyen, M.D., assistant professor of ophthalmology, and Peter Campochiaro, M.D., professor of ophthalmology, at Wilmer. As OXiGENE announced in October 2002, the trial is being funded by The Foundation Fighting Blindness, Inc. (FFB), the nation's premier non-profit eye research organization, whose mission is to discover the causes, treatments and cures for degenerative retinal eye diseases.

"CA4P has exhibited very promising pre-clinical results in preventing and causing regression of choroidal neovascularization, the major cause of severe vision loss in patients with age-related macular degeneration," said Dr. Jerry Chader, the FFB's chief scientific officer and a former sci
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
2-Jul-2003


Page: 1 2 3

Related biology news :

1. OXiGENE launches significant expansion of its R&D program in ophthalmology
2. OXiGENE announces commencement of Phase I/II clinical trial of Combretastatin A4 Prodrug
3. OXiGENE announces phase II clinical trial of lead anti-tumor compound in thyroid cancer
4. OXiGENE, foundation fighting blindness sign research agreement for phase I/II clinical trial
5. Secretary of Energy announces seven E.O. Lawrence Award Winners
6. Popular Science announces Third Annual Brilliant 10
7. The American Phytopathological Society announces 2004 awards
8. NSF announces six FIBR awards to tackle some of biologys most challenging questions
9. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
10. JGI announces community sequencing program portfolio
11. APS announces the winners of its 2004 postdoctoral fellowship in physiological genomics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/11/2020)... ... March 11, 2020 , ... USARAD Holdings ... Siemens Healthineers and several healthcare VC firms introduces a first of its kind ... 100 countries and has caused over 4,000 fatalities to date. Over the years, ...
(Date:3/5/2020)... , ... March 05, 2020 , ... ... a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ existing products and ... in San Diego, California. Phoenestra is a biotech company located in Austria. ...
(Date:3/5/2020)... ... March 05, 2020 , ... In September 2016, ... The AlphaSTEM Test™ is the first, and still only, available technology that provides ... attempt to provide information about the number and quality of therapeutic tissue stem ...
Breaking Biology News(10 mins):
(Date:3/3/2020)... (PRWEB) , ... March 03, 2020 , ... ... was invited to present the latest breast implant technology at the IMCAS Innovation ... and new innovations in the dermatology, plastic surgery, and aesthetic science industries that ...
(Date:2/21/2020)... ... February 20, 2020 , ... ... efficient and elegant chemistry. Humans have been increasingly successful in innovating ways ... Through rapidly evolving technologies and strategies for modern molecular biology (e.g., gene ...
(Date:2/19/2020)... (PRWEB) , ... February 18, 2020 , ... ... medical devices, today announced the launch of a new and unified global brand ... tackle the industry’s most complex engineering challenges, as well as an enthusiasm for ...
(Date:2/10/2020)... ... ... R3 Medical Training announced it is now registering for its next Comprehensive ... hands on involving real patients and stem cell biologics, with every attendee receiving a ... Course has received rave reviews from attendees, who love the hands on nature of ...
Breaking Biology Technology:
Cached News: